spacer
home > ict > spring 2017 > odd one out
PUBLICATIONS
International Clinical Trials

Odd One Out

Over recent years, permissive science, innovative trial methodology, evolving regulatory sentiments and increasingly sophisticated commercialisation have all contributed to drug development. However, some challenges still remain. Poor understanding regarding the natural history of the proposed indication due to few observational trials studying disease progression, recruiting and retaining patients and investigators as well as regulatory uncertainties can all prove difficult, to detail just a few.

Facilitating Enrolment

A smaller selection of patients and, occasionally, a decreased likelihood of finding and engaging patient advocacy groups, means that identifying and locating participants can be extremely perplexing for orphan drug researchers.

The benefits of working with patient advocy groups are invaluable to researchers when attempting to seek out participants. These groups usually involve patient caregivers or relatives, as well as doctors and key opinion leaders (KOLs) in the specific indication. It is crucial for CROs, sponsors and investigators to reach out and communicate with these groups – especially during the initial stages of a protocol design – because having their cooperation at this point can be crucial to the success of a trial. By taking the time to meet and speak with members of any relevant groups, researchers can gain valuable insight into a particular condition – including what life is like for potential participants, as well as what is important to the caregivers and others in the patient’s network.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jeffrey Zucker is Senior Vice President of Global Clinical Operations at Worldwide Clinical Trials. His current responsibilities include growing and continually improving the company’s global and site feasibility capabilities. Jeffrey also oversees the evolving Patient Recruitment and Site Relations departments and has been in the clinical research industry for 20 years.
spacer
Zeffrey Zucker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals appoints José Luis Bartolomé as Operational Excellence Director

[Noáin, Spain, September 30, 2020]3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, appoints a new member to the management team with the incorporation of José Luis Bartolomé as Operational Excellence and Continuous Improvement Director.
More info >>

White Papers

How To Increase Efficiency, Customer Satisfaction and Reduce Cost

AC Labels

A customer of Riverside Medical had required a complex four-part 'piggy back' label. The labels needed to be specially constructed to facilitate removal in parts at various stages of its use for quality control traceability. This label needed to carry variable data elements of LOT numbers, batch numbers and product descriptions, and also a secondary gamma indicator label placed on each of its 4 sections to prove its sterility following sterilisation.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement